Advances in uterine leiomyoma research: Conference overview, summary, and future research recommendations

Environmental Health Perspectives

Volumn 108, Issue SUPPL. 5, 2000, Pages 769-773

  Newbold, Retha R ^a   DiAugustine, Richard P ^a   Risinger, John I ^a   Everitt, Jeffrey I ^b   Walmer, David K ^c   Parrott, Estella C ^d   Dixon, Darlene ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Conference summary; Overview; Research recommendations; Uterine leiomyoma

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BRCA1 PROTEIN; DIETHYLSTILBESTROL; ESTROGEN; ESTROGEN RECEPTOR; HIGH MOBILITY GROUP PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; ONCOPROTEIN; PROGESTERONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GROWTH REGULATION; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MOUSE; MOUSE STRAIN; MUSCLE TUMOR; NONHUMAN; PRIORITY JOURNAL; RAT; RHESUS MONKEY; TUMOR GROWTH; UNITED STATES; UTERUS BIOPSY; UTERUS MYOMA;

ANIMALIA; MACACA MULATTA;

EID: 0033664228     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.00108s5769     Document Type: Article

References (63)

1. The female genital tract
2. The frequency of uterine leiomyomas
3. Uterine leiomyomata: Etiology, symptomatology, and management
4. Epidemiologic characteristics of women with uterine fibroids: A case-control study
5. Early normal menstrual cycle pattern and the development of uterine leiomyomas
6. Uterine fibromyomata: Presentation and management in northern Nigeria
7. Hysterectomy: Improving the patients' decision-making process
8. Developmental effects of endocrine-disrupting chemicals in wildlife and humans
9. Long-term effects on the female mouse genital tract associated with prenatal exposure to diethylstilbestrol
10. Reduced fertility in female mice exposed transplacentally to diethylstilbestrol (DES)
11. Vaginal adenosis and adenocarcinoma in mice exposed prenatally or neonatally to diethylstilbestrol
12. Diethylstilbestrol associated defects in murine genital tract development
13. Cellular and molecular effects of developmental exposure to diethylstilbestrol: Implications for other environmental estrogens
14. Uterine adenocarcinoma in mice following developmental treatment with estrogens: A model for hormonal carcinogenesis
15. Adenocarcinoma of the vagina: Association of maternal stilbestrol therapy with tumor appearance in young women
16. Abnormal gene expression in uterine leiomyomas
17. Progesterone: A critical role in the pathogenesis of uterine myomas
18. Growth factors and cytokines in uterine leiomyomas
19. New concepts in the treatment of uterine leiomyomas
20. The dose-effect relationship between 'unopposed' estrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk
21. Estrogen induces insulin-like growth factor-I expression in the rat uterus
22. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-I receptor and insulin receptor substrate in the uterus
23. Insulin-like growth factor-I (IGF-1) receptor-insulin receptor substrate complexes in the uterus. Altered signaling response to estradiol in the IGF(m/m) mouse
24. 2 progression in the estradiol-induced mitotic cycle
25. Effects of an Igf1 gene null mutation on mouse reproduction
26. Sex steroid regulation of insulin-like growth factor system gene expression and proliferation in primate myometrium
27. Insulin-like growth factor I and II binding in human myometrium and leiomyomas
28. A comparative ultrastructural study of leiomyosarcoma, cellular leiomyoma, and leiomyoma of the uterus
29. Uterine leiomyomas: Cytogenetic and histologic profile
30. Chromosome analysis of 96 uterine leiomyomas
31. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains
32. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours
33. Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanisms different from that in lipomas
34. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas
35. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis
36. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C
37. HMGI(Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign neoplasm
38. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization
39. Allelotype of uterine leiomyomas
40. Allelotype analysis of uterine leiomyoma: Localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q
41. Mesovarian leiomyomas in the rat
42. High incidence of spontaneous cervical and vaginal tumors in an inbred strain of Brown Norway rats (BN/Bi)
43. Rodent model of reproductive tract leiomyomata: Clinical and pathologic features
44. Rodent model of reproductive tract leiomyomata: Establishment and characterization of tumor-derived cell lines
45. Establishment of human uterine leiomyosarcoma heterotransplanted into nude mice
46. Estrogen-induced guinea pig model for uterine leiomyomas: Do the ovaries protect?
47. Smooth muscle and bone neoplasms in transgenic mice expressing SV40 T antigen
48. Estradiol-dependent uterine leiomyomas in transgenic mice
49. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo
50. Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor gamma, retinoid X receptor alpha, and all-trans retinoic acid than myometrium
51. Effects of raloxifene in a guinea pig model for leiomyomas
52. Estrogen/antie-strogen responsiveness in an in vivo/in vitro model for myometrial tumorigenesis
53. Regulation of apoptosis in uterine leiomyomata
54. Rodent model of reproductive tract leiomyomata: Characterization and use in pre-clinical therapeutic studies
55. Endoscopic myomectomy. Laparoscopy and hysteroscopy
56. Ambulatory management of uterine leiomyomata
57. Uterine artery embolization for the treatment of uterine leiomyomata midterm results
58. Initial results from uterine fibroid embolization for symptomatic leiomyomata
59. Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells